15
Participants
Start Date
September 20, 2018
Primary Completion Date
September 30, 2020
Study Completion Date
December 31, 2025
Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC)
TDF-FTC pod-IVR designed to deliver TDF at a target rate of 1 mg d-1 and FTC at a target rate of 2 mg d-1.
Placebo
A placebo pod-IVR containing microcrystalline cellulose pods.
University of Texas Medical Branch, Galveston
The Miriam Hospital
OTHER
Johns Hopkins University
OTHER
University of California, Los Angeles
OTHER
University of California, San Diego
OTHER
Vanderbilt University
OTHER
The University of Texas Medical Branch, Galveston
OTHER
National Institutes of Health (NIH)
NIH
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Oak Crest Institute of Science
OTHER